BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28406576)

  • 1. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
    Saijo K; Imai H; Chikamatsu S; Narita K; Katoh T; Ishioka C
    Cancer Sci; 2017 Jul; 108(7):1469-1475. PubMed ID: 28406576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
    Imai H; Saijo K; Chikamatsu S; Kawamura Y; Ishioka C
    Cancer Sci; 2021 Feb; 112(2):792-802. PubMed ID: 33274548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
    Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Synthetic Study on Bicyclic Depsipeptides Containing an Intramolecular Disulfide Bond].
    Narita K
    Yakugaku Zasshi; 2022; 142(9):917-926. PubMed ID: 36047217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
    Son DS; Wilson AJ; Parl AK; Khabele D
    Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
    Erlich RB; Kherrouche Z; Rickwood D; Endo-Munoz L; Cameron S; Dahler A; Hazar-Rethinam M; de Long LM; Wooley K; Guminski A; Saunders NA
    Br J Cancer; 2012 Jan; 106(1):107-15. PubMed ID: 22116303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
    Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
    Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
    Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
    Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
    Wang N; Mo Z; Pan L; Zhou M; Ye X; Liu X; Cai X; Qian C; Chen F; Xiong Y; Fan F; Li W
    Target Oncol; 2023 Nov; 18(6):941-952. PubMed ID: 37855991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of burkholdacs A and B and 5,6,20-tri-epi-burkholdac A: HDAC inhibition and antiproliferative activity.
    Fukui Y; Narita K; Dan S; Yamori T; Ito A; Yoshida M; Katoh T
    Eur J Med Chem; 2014 Apr; 76():301-13. PubMed ID: 24589486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
    Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
    Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.